Canavan disease
| Canavan disease | |
| ICD-9 | 330.0 |
|---|---|
| OMIM | 271900 |
| DiseasesDB | 29780 |
| MedlinePlus | 001586 |
|
WikiDoc Resources for Canavan disease |
|
Articles |
|---|
|
Most recent articles on Canavan disease Most cited articles on Canavan disease |
|
Media |
|
Powerpoint slides on Canavan disease |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Canavan disease at Clinical Trials.gov Trial results on Canavan disease Clinical Trials on Canavan disease at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Canavan disease NICE Guidance on Canavan disease
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Canavan disease Discussion groups on Canavan disease Patient Handouts on Canavan disease Directions to Hospitals Treating Canavan disease Risk calculators and risk factors for Canavan disease
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Canavan disease |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Canavan disease is an inherited disorder that causes progressive damage to nerve cells in the brain. This disease is one of a group of genetic disorders called leukodystrophies. Leukodystrophies are characterized by degeneration of myelin, which covers the phospholipid layer of neuron insulating the axon.
Epidemiology
Although Canavan disease may occur in any ethnic group, it affects persons of Eastern European Jewish ancestry more frequently. About 1/40 individuals of Eastern European (Ashkenazi) Jewish ancestry are carriers. Canavan disease is inherited in an autosomal recessive fashion. If both parents are carriers, there is a 25% chance of having an affected child. Genetic counseling and genetic testing is recommended for families who may be carriers.
Cause
Canavan disease is caused by a defective ASPA gene which is responsible for the production of the enzyme aspartoacylase. This enzyme breaks down the concentrated brain molecule N-acetyl aspartate. Decreased aspartoacylase activity prevents the normal breakdown of N-acetyl aspartate, and the lack of breakdown somehow interferes with growth of the myelin sheath of the nerve fibers in the brain. The myelin sheath is the fatty covering surrounding nerve cells that acts as an insulator, and allows for efficient transmission of nerve impulses.
Symptoms
Symptoms of Canavan disease, which appear in early infancy and progress rapidly, may include mental retardation, loss of previously acquired motor skills, feeding difficulties, abnormal muscle tone (i.e., floppiness or stiffness), poor head control, and megalocephaly (abnormally enlarged head). Paralysis, blindness, or seizures may also occur.
Treatment
There is no cure for Canavan disease, nor is there a standard course of treatment. Treatment is symptomatic and supportive. The life expectancy of Canavan patients is not known because new treatments have extended their lives beyond earlier projections. Today, Canavan children often survive into their teens and beyond.
Research involving triacetin supplementation in patients with Canavan disease has shown some promising results. Glyceryl Tricetate study Triacetin, which can be enzymatically cleaved to form acetate, enters the brain more readily than the negatively charged acetate.
Prognosis
Death usually occurs before age 4 untreated, although some children may survive into their twenties via newer treatments which have extended life expectancy. There is no known cure.
Current research
A team of researchers headed by Paola Leone are currently at the University of Medicine and Dentistry of New Jersey, in Camden, New Jersey. The brain gene therapy is conducted at Cooper University Hospital. The procedure involves the insertion of six catheters into the brain that deliver a solution containing 600 billion to 900 billion engineered virus particles. The virus, a modified version of AAV, is designed to replace the aspartoacylase enzyme. Children treated with this procedure to date have shown marked improvements, including the growth of myelin with decreased levels of the n-acetyl-aspartate toxin.
See also
External links
- Information on the disorder from the National Institute of Neurological Disorder and Stroke
- Cell & Gene Therapy Center at UMDNJ
- Beat Canavan Disease - A web site dedicated to raising funds to save a Canavan baby's life
- Canavan Research Illinois - A public charity devoted to curing Canavan disease
- Canavan Research - A foundation devoted to curing Canavan disease
- Jacob's Cure - A non-profit organization dedicated to raising money for Canavan disease research